A non-invasive wearable neurotech company called ActivateNeuro, Inc. launched on 25 June 2026 in Columbus, Ohio with a $2.9 million seed round and a licence to commercialise Battelle’s NeuroLife platform for hand and arm rehabilitation in stroke and spinal cord injury patients. ActivateNeuro is the trading entity behind the NeuroLife brand. The seed round was anchored by Battelle Memorial Institute and the NeuroTech Institute (NTI) as founding partners. The company’s launch announcement does not name an external lead venture investor. ActivateNeuro is led by Chief Executive Officer Jon Snyder, the founder and former CEO of Cleveland-based Neuros Medical, which develops high-frequency electrical nerve block for chronic pain. The company stated that the seed capital will be used to pursue FDA clearance, complete clinical validation, and develop commercial scalability.

What the NeuroLife sleeve actually does

The NeuroLife platform is a non-invasive wearable sleeve that wraps around the user’s forearm and uses surface electromyography (sEMG) to read electrical activity from forearm muscles. When the user attempts a hand movement, the sleeve detects the muscle-activation pattern and delivers functional electrical stimulation (FES) to drive the intended motion. The device does not implant electrodes, does not penetrate the dura, and does not require neurosurgical intervention. Battelle’s product page describes the system as designed for guided hand and arm therapy sessions in stroke and spinal cord injury patients with residual but limited motor control.

The clinical use case is hand and arm motor rehabilitation. The target patient population includes stroke survivors with hand and arm impairment, which affects roughly half to two-thirds of stroke survivors at six months post-event, and spinal cord injury patients with residual upper-extremity function. The launch materials describe the sleeve as positioned for the guided-therapy setting rather than for at-home continuous use, which signals an initial commercial path through rehabilitation clinics rather than direct-to-consumer.

What this is not: the Burkhart Utah Array program

The original public-facing Battelle NeuroLife program is best known to the brain-computer interface community for the Ian Burkhart case study at The Ohio State University Wexner Medical Center. Burkhart received a Utah Array intracortical implant in 2014 and used neural-signal decoding to restore voluntary hand movement after a cervical spinal cord injury, with results published in Nature in 2016. That work was an invasive cortical brain-computer interface.

The 2026 ActivateNeuro launch does not commercialise that invasive cortical implant programme. ActivateNeuro is licensing the non-invasive sleeve sibling of the NeuroLife platform, the sEMG-and-FES wearable line that Battelle has run in parallel to the cortical implant research. The non-invasive sleeve operates on muscle-signal decoding rather than cortical-signal decoding, targets peripheral nerves and muscles rather than cortical tissue, and follows the rehabilitation device FDA clearance pathway rather than the first-in-human implantable BCI clinical pathway.

Brand reuse is a documented source of reader confusion for any analyst tracking the Battelle BCI lineage. The NeuroLife brand carries forward into the ActivateNeuro spinout, but the technology spun out is the non-invasive sibling, not the Utah Array implant.

Who Jon Snyder is and how ActivateNeuro fits the NeuroTech Institute pipeline

Jon Snyder is the founder and former Chief Executive Officer of Cleveland-based Neuros Medical, the developer of the Altius high-frequency electrical nerve block system for chronic pain. His ActivateNeuro appointment is the named operational leadership for the commercial launch. The launch materials do not disclose the broader founding team, chief technology officer, or scientific advisors. Matt McFarland of Battelle is quoted in the BusinessWire release as the institutional Battelle voice on the spinout, but is not a NeuroLife executive.

ActivateNeuro is a portfolio company of the NeuroTech Institute (NTI), the non-profit neurotechnology accelerator launched by The Ohio State University and Battelle in October 2022. NTI is based on the OSU campus and has raised more than $28 million across its operating cycles. The institute’s stated mission is to translate Ohio-based neurotechnology research into commercial spinouts at a target rate of five to ten companies per year. ActivateNeuro is one of the spinouts produced through that pipeline. Tim Lucas, MD, PhD, has served as inaugural CEO of NTI.

A nonprofit accelerator with university and applied-research-institute parents creates a different capital path than a pure venture-funded biotech. ActivateNeuro can draw on Battelle’s regulatory and clinical-trial infrastructure, OSU’s clinical sites, and NTI’s commercial development capacity, with the trade-off that institutional control of the spinout sits with the founding partners rather than with an external venture lead.

Where this sits on the wearable-rehabilitation map

The wearable rehabilitation device category for stroke and spinal cord injury has several established commercial entries. Bioness L300 and H200 (acquired by Bioventus in March 2021) deliver functional electrical stimulation for foot drop and hand rehabilitation. Saebo offers dynamic spring-loaded and tensioning orthoses (SaeboFlex, SaeboGlove). Myomo’s MyoPro is a myoelectric motorised arm-and-hand orthosis. MicroTransponder Vivistim is an FDA-approved implantable vagus nerve stimulator that pairs with rehabilitation therapy and demonstrated stroke-rehabilitation efficacy in the VNS-REHAB pivotal trial published in The Lancet in 2021. ActivateNeuro enters this category as a non-invasive sEMG-driven FES device on a guided-therapy commercial path.

The launch is small in capital terms. A $2.9 million seed from institutional founding partners with no external venture lead is at the floor of US institutional venture activity. The signalling weight of the round comes from the Battelle and NTI institutional anchoring and from the NeuroLife platform’s name recognition inside the BCI and rehabilitation device community, not from the headline dollar figure.

What to watch

The first signal is the specific FDA pathway ActivateNeuro pursues. The launch announcement says the company is “pursuing FDA clearance” without specifying 510(k), De Novo, or Breakthrough Device Designation. Each pathway implies a different timeline and a different regulatory positioning relative to existing FES devices. A 510(k) submission citing the Bioness L300 family as predicate would signal one commercial strategy. A De Novo or Breakthrough designation citing the sEMG-FES coupling as a novel device-classification claim would signal a different strategy.

The second signal is whether ActivateNeuro publicly discloses interim clinical trial enrolment or data within the next twelve months. Clinical validation in stroke rehabilitation typically requires a structured outcome measure such as the Fugl-Meyer Assessment or Action Research Arm Test, with effect-size comparisons against guided rehabilitation alone. ActivateNeuro’s competitive positioning against Vivistim, Bioness, and Myomo will depend on those metrics.

The third signal is whether other NTI portfolio spinouts emerge with similar Battelle technology licensing structures in the next year. ActivateNeuro is the first publicly named spinout from the NTI pipeline. If the pipeline is operating as designed, the cadence of named launches will indicate whether the NTI commercial-translation model is scaling.

Sources

• ActivateNeuro launches NeuroLife technology to restore hand and arm movement (BusinessWire, 25 June 2026)
• Wearable neurotech company NeuroLife launches with $2.9M to restore movement after stroke (MassDevice, Sean Whooley, 25 June 2026)
• Battelle NeuroLife product page
• Ohio State and Battelle establish new NeuroTech Institute (OSU News, October 2022)
• Battelle NeuroLife uses thought to control paralysed limbs (MassDevice, historical context on Burkhart programme)
• Neuros Medical brings new CEO (Crain’s Cleveland Business, 2017, on Jon Snyder)